Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
January 03 2023 - 4:01PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
today announced that it will report its fourth quarter and full
year 2022 financial and operating results on Friday, February 3,
2023, before the U.S. financial markets open. The Company will host
a conference call and simultaneous webcast at 8:30 AM Eastern Time
that day.
Conference Call InformationParticipants may
access the conference call live via webcast on the ’Investors and
Media’ page of Regeneron’s website at
https://investor.regeneron.com. To participate via telephone,
please register in advance at this link. Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay of the conference call and webcast will be
archived on the Company’s website for at least 30 days.
About Regeneron Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents,
develops and commercializes life-transforming medicines for people
with serious diseases. Founded and led for nearly 35 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully human antibodies and
bispecific antibodies, and through ambitious research initiatives
such as the Regeneron Genetics Center, which is conducting one of
the largest genetics sequencing efforts in the world.
For more information, please visit www.Regeneron.com or follow
@Regeneron on Twitter.
Contact Information:Investor RelationsRyan
Crowe914.847.8790ryan.crowe@regeneron.com
Corporate Communications Alexandra
Bowie914.847.3407alexandra.bowie@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024